HC Wainwright Weighs in on Pharming Group Q4 Earnings

Key Points

• HC Wainwright maintained a Buy rating and a $37 price target for Pharming Group, forecasting fourth-quarter 2026 EPS of $(0.01) and fiscal 2027 EPS of $0.59.
• Pharming’s latest quarterly results exceeded expectations, with EPS of $0.30 versus the $0.15 consensus estimate, while revenue reached $117.6 million in line with forecasts.
• Analyst sentiment remains mixed: Pharming has a consensus Hold rating and an average price target of $38.67, despite strong Joenja and RUCONEST revenue growth and a narrowed 2026 revenue outlook of $380 million–$390 million.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Research analysts at HC Wainwright issued their Q4 2026 earnings estimates for shares of Pharming Group in a note issued to investors on Tuesday, October 27th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright currently has a "Buy" rating and a $37.00 price target on the stock. The consensus estimate for Pharming Group's current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Pharming Group's FY2027 earnings at $0.59 EPS.

Several other research analysts have also commented on the stock. Zacks Research raised shares of Pharming Group from a "strong sell" rating to a "hold" rating in a research note on Friday, October 23rd. Weiss Ratings raised shares of Pharming Group from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday. Oppenheimer restated an "outperform" rating on shares of Pharming Group in a report on Wednesday. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research note on Wednesday, September 23rd. Finally, Wall Street Zen raised shares of Pharming Group to a "hold" rating in a research report on Saturday. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Pharming Group presently has a consensus rating of "Hold" and a consensus price target of $38.67.

Pharming Group Stock Performance

Shares of Pharming Group stock opened at $11.87 on Wednesday. The stock has a market cap of $840.13 million, a price-to-earnings ratio of 98.92 and a beta of -0.05. The stock has a 50 day moving average price of $10.69 and a 200-day moving average price of $13.89. Pharming Group has a one year low of $9.11 and a one year high of $21.34.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. The company had revenue of $117.60 million for the quarter, compared to the consensus estimate of $117.60 million.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP bought a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group makes up approximately 6.0% of MAC Alpha Capital Management LP's investment portfolio, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 0.03% of the company's stock.

More Pharming Group News

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Third-quarter revenue rose 21% year over year to $117.6 million, in line with estimates, while adjusted earnings of $0.30 per share exceeded the $0.15 consensus estimate. Operating profit increased 89% to $29.9 million. Pharming Group earnings results
• Positive Sentiment: Joenja revenue climbed 58% to $23.8 million, supported by strong U.S. and international demand. The company also reported progress toward expansion, including a U.S. pediatric label and launches in Germany and Japan. Pharming third-quarter financial results
• Positive Sentiment: RUCONEST revenue increased 14% to $93.8 million, suggesting demand has stabilized, while operating cash flow strengthened the balance sheet and lifted cash to $190.9 million.
• Positive Sentiment: Pharming expects to release topline Phase II data for leniolisib in the broader common variable immunodeficiency (CVID) population in November. Positive data could expand Joenja’s addressable market, although the result remains a material clinical catalyst. Pharming growth and CVID data
• Neutral Sentiment: Pharming narrowed its 2026 revenue guidance to $380 million-$390 million from $375 million-$395 million. The midpoint is unchanged, so the update signals improved visibility rather than a clear increase in expectations. Pharming Q3 earnings call transcript
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no evidence of meaningful short-covering demand or bearish positioning. Pharming short interest

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming's principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.